Healthcare Professionals
Evolut™ R System
Transcatheter Aortic Valve Implantation (TAVI)
You just clicked a link to go to another website. If you continue, you may go to a site run by someone else.
We do not review or control the content on non-Medtronic sites, and we are not responsible for any business dealings or transactions you have there. Your use of the other site is subject to the terms of use and privacy statement on that site.
It is possible that some of the products on the other site are not approved in your region or country.
This site uses cookies to store information on your computer. Some are essential to make our site work; others help us improve the user experience. By using the site, you consent to the placement of these cookies. You may at any time change the settings regarding cookies. Read our privacy statement to learn more.
Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
The content of this website is exclusively reserved for Healthcare Professionals in countries with applicable health authority product registrations, except those practicing in France as some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.
Click “OK” to confirm you are a Healthcare Professional.
Healthcare Professionals
Evolut™ R System
Transcatheter Aortic Valve Implantation (TAVI)
The Evolut™ R Transcatheter Aortic Heart Valve, built on the proven foundation of the CoreValve™ platform, can be recaptured and repositioned. Its self-expanding nitinol frame enhances the ability to conform and seal to the native annulus. The supra-annular leaflet position keeps the working portion of the valve above and unconstrained by the native annulus.
The EvolutTM R valve is built on a proven platform, which continues to demonstrate exceptional outcomes.
Manufacturing the CoreValve Evolut R TAV
See the Evolut TAVI manufacturing process and our commitment to quality in every step.
More information (see more)
Less information (see less)
The supra-annular valve design and oversizing feature of the nitinol frame maximize the valve orifice and leaflet coaptation.1
The EvolutTM R valve design promotes single-digit gradients and large effective orifice areas (EOAs): The supra-annular valve optimizes coaptation in non-circular anatomy with supra-annular valve position and conforms to the native annulus.
Features of the EnVeoTM PRO delivery system allow you to treat more patients and position the valve more accurately.
Broadest annulus range*
More patients have access to the minimally invasive TAVI procedure because of the expanded annulus range.
*Broadest annulus range based on CT derived diameters.
Lowest delivery profile
The EvolutTM R system retains its outer diameter as it enters the vessel and remains at this diameter as it is advanced to the annulus.
EnVeo PRO Delivery System
Recapture and reposition
The EnVeoTM PRO delivery system assists in accurate positioning of the valve. The delivery system features a 1:1 response, thus providing immediate feedback between the deployment knob and the movement of the capsule.
In addition, the EnVeoTM PRO delivery system provides you the option to recapture and reposition2 for more accurate placement.
The Confida Brecker Guidewire (CBG) is specifically designed for TAVI procedures. To minimize risk of ventricular perforation, the CBG features a continuous tapered core. The guidewire curve is pre-shaped to help with anchoring during valve deployment.
The Confida Brecker Guidewire (CBG) is specifically designed for TAVI procedures. To minimize risk of ventricular perforation, the CBG features a continuous tapered core. The guidewire curve is pre-shaped to help with anchoring during valve deployment.
Popma JJ, Reardon MJ, Khabbaz K, et al. Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study. JACC Cardiovasc Interv. February 13, 2017;10(3):268-275.
Up to 80% deployment. The valve can be partially or fully recaptured up to three times prior to the point of no recapture. Third attempt must be a complete recapture and retrieval from patient.